The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Overcoming innate immune barriers that impede AAV gene therapy vectors
Open accessAbstract
The field of gene therapy has made considerable progress over the past several years. Adeno-associated virus (AAV) vectors have emerged as promising and attractive tools for in vivo gene therapy. Despite the recent clinical successes achieved with recombinant AAVs (rAAVs) for therapeutics, host immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies. These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines. The human immune system is multidimensional and complex. Both the innate and adaptive arms of the immune system seem to play a concerted role in the response against rAAVs. While most efforts have been focused on the role of adaptive immunity and developing ways to overcome it, the innate immune system has also been found to have a critical function. Innate immunity not only mediates the initial response to the vector, but also primes the adaptive immune system to launch a more deleterious attack against the foreign vector. This Review highlights what is known about innate immune responses against rAAVs and discusses potential strategies to circumvent these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“further supported with the reports of complement-mediated TMA cases in subjects receiving high doses of systemic AAV (40, 41)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the goal of commonly used immunomodulation regimes was to inhibit T cell function and included mostly corticosteroids, sirolimus, tacrolimus, mycophenolate mofetil, or cyclosporine (40, 41).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, rAAV capsid-targeting TLR2, various DNA sensors, and complement activation may also play a role (22).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“Figure 1, activated IRAKs lead to transcription of several proinflammatory cytokines, including TNF-α and IL-6 (35).”
BackgroundPattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895 · cited 1×
“These signals lead to the expression of host defense genes, like the MHC genes, proinflammatory cytokines, chemokines, and type I and III IFNs (31).”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs that have been implicated in initiating inflammatory responses to viruses are TLR2 (glycoproteins and lipoproteins), TLR3 (dsRNA), TLR4 (glycoproteins and bacterial LPS), TLR7 (ssRNA), TLR8 (ssRNA), and TLR9 (unmethylated CpG [cytosine-phosphate-guanine] DNA) (39).”
BackgroundRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297 · cited 2×
“Secreted cytokines and chemokines are also critical for inducing effective adaptive and memory immune responses (33).”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233 · cited 4×
“TLR1, 2, 4, 5, 6, and 10 (glycoprotein-recognizing receptors) are commonly located on the cell surface, whereas TLR3, 7, 8, and 9 (nucleic acid–specific receptors) are generally found on the endosomal membrane (38).”
BackgroundInfluentialSTING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“Mice deficient in cGAS and STING are more susceptible to lethal herpes simplex virus 1 (HSV1) infection because of a decrease in type I IFN response (71, 72).”
BackgroundIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
Self-citationAIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., & Fitzgerald, K. A. (2009) · Nature · doi:10.1038/nature07725 · Cited by 2,627 · cited 14×
“Further studies are required to elucidate whether AAV infection activates the AIM2 inflammasome pathway.”
BackgroundInfluentialSelf-citationAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citation
Research works printed but not linked: 6
- Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. Press release. Audentes Therapeutics. August 20, 2020. https://www.audentestx.com/press_release/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy/ Accessed November 2, 2020
- Pfizer’s new phase 1b results of gene therapy in ambulatory boys with duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Press release. Pfizer. May 15, 2020. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study/default.aspx Accessed November 2, 2020
- Chan, 2019, Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome, Mol Ther, 27
- Letizia, 2019, Engineering AAV vectors to reduce CD8+ T cell responses following intramuscular injection in mice, Mol Ther, 27
- Pfizer presents initial clinical data on phase 1b gene therapy study for duchenne muscular dystrophy (DMD). Press release. Pfizer. June 28, 2019. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd Accessed November 2, 2020
- Solid Biosciences provides SGT-001 program update. Press release. Solid Biosciences. November 12, 2019. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Accessed November 2, 2020
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Self-citationTabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
“These two attributes suggest that this class of AAV capsids could lower the dose of virus needed to achieve therapeutic levels of target cell transduction, lessening therapy-related risk for classical activation of complement by capsid/antibody complexes (Muhuri et al., 2021) andmitigating potentially detrimental cons…”
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
“A comprehensive summary of the pharmacological approaches to minimize immune responses against AAV can be found in a recent review 92 .”
BackgroundrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“This situation is further exacerbated by the fact that repeated dosing is challenging due to immune responses against AAV (8).”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
Metadata
- Authors
- Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-04
- Volume
- 131
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7773343
- OpenAlex
- W3120585537
- Cited by
- 212
- References
- 172
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 59 · 2023: 30 · 2022: 28 · 2021: 11
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (AI067497)
- National Heart, Lung, and Blood Institute (P01HL131471, R01HL097088, UG3HL147367)
- National Institute of Allergy and Infectious Diseases (R01AI132296, R33AI136007, R01AI067497, R01AI128358, R37AI067497, P01AI100263, R01AI141181, U19AI149646, R56AI067497)
- National Institute of Neurological Disorders and Stroke (R01NS076991)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus vectors, recombinant adeno-associated virus, innate immunity, immune evasion, gene therapy vectors, host immune response, in vivo gene therapy, immunogenicity
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Immunity, Innate, Genetic Therapy, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming innate immune barriers that impede AAV gene therapy vectors. https://app.cochat.ai/papers/10.1172/jci143780
- The paper
- Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021). Overcoming innate immune barriers that impede AAV gene therapy vectors. Journal of Clinical Investigation. https://doi.org/10.1172/jci143780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.